Roche to continue obesity studies for emugrobart despite mid-stage trial setbacks
Source: SeekingAlpha
2026-03-20 12:48:43 ET
More on Roche Holding
- Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
- Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline - Slideshow
- Roche Falters In A Key Breast Cancer Readout
- Roche deploys Nvidia-powered AI factory for drug development
- Roche receives CE approval for Elecsys ApoE4 biomarker test
Read the full article on Seeking Alpha
For further details see:
Roche to continue obesity studies for emugrobart despite mid-stage trial setbacks
Roche Holding Ltd ADR
NASDAQ: RHHBY
RHHBY Trading
0.97% G/L:
$48.225 Last:
1,101,151 Volume:
$48.05 Open:
RHHBY Latest News
March 24, 2026 02:00:00 am
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
March 18, 2026 09:00:00 am
Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
RHHBY Stock Data
$361,973,933,704
6,306,832,002
N/A
43
N/A
Pharmaceuticals
Healthcare
CH
Basel Switzerland
